Cardinal Health vs. McKesson: Which Healthcare Stock Is Better?

Cardinal Health is favored over McKesson based on stronger earnings momentum, lower relative valuation and steadier estimates: CAH reported fiscal Q4 revenue of $63.7B (+6%), gross profit growth of 16% and operating-income growth of 30%. McKesson delivered fiscal Q1 revenue of $105B (+8%) and adjusted EPS of $9.93 (+20%), raising full-year adjusted EPS guidance to $44.20-$45.00, but its near-term EPS estimate fell $0.03 over seven days. CAH's fiscal Q1 2027 EPS is projected to rise 14.5% versus 8.7% for MCK, while CAH trades at 17.2x forward earnings compared with MCK's 18.7x.

Analysis

The investable distinction is not near-term distributor revenue growth but the durability and quality of gross-profit mix. CAH’s physician-facing specialty, nuclear medicine and home-care businesses can support incremental margin and reduce dependence on low-spread branded-drug distribution; if execution holds, this justifies a further relative multiple narrowing versus MCK over the next 2-3 earnings prints. MCK’s scale and oncology franchise remain structurally attractive, but its larger absolute earnings base makes a comparable percentage reacceleration harder and creates more event risk around the Medical-Surgical separation.

The market may be underweight the reimbursement and drug-price-policy correlation embedded in both names. A policy change that compresses pharmacy/provider economics can pressure specialty volumes and distributor service fees simultaneously, while tariffs on medical products are a more direct risk to CAH’s non-distribution businesses. Conversely, growth in oncology, radiopharmaceuticals and complex biologics should favor distributors with clinical workflow integration over pure logistics players; this is a 6-18 month share-of-profit shift, not a one-quarter sales catalyst.

Near term, the article’s estimate-revision signal is too small to support an outright MCK short: MCK has a higher likelihood of defending estimates through operating leverage and buybacks, and separation clarity could unlock a sum-of-parts rerating. The cleaner expression is relative. A sustained CAH gross-profit growth premium and intact margins through the next two reports could drive 5-10% relative upside; failure of specialty profit conversion or acquisition-integration slippage would quickly remove that premium.

Key Decisions for Investors

• Initiate a 3-6 month market-neutral pair: long CAH / short MCK in equal dollar amounts. Target 8-12% relative return as CAH’s mix-driven earnings growth narrows the valuation gap; reassess if CAH’s next two quarterly gross-profit growth rates fall below low teens or MCK restores upward consensus revisions.
• For long-only exposure, add CAH only on post-earnings weakness rather than chase the narrative; use the next quarterly report to verify specialty-margin conversion, cash-flow quality and Solaris integration. A guidance reduction or a material rise in working-capital consumption falsifies the thesis.
• Maintain MCK as a watch-list long into Medical-Surgical separation milestones rather than a fundamental short. Upgrade only if management quantifies separation costs, standalone margin/FCF targets and capital-return plans sufficient to offset policy uncertainty; absent this disclosure, the catalyst is not yet tradable.
• Monitor reimbursement-rule headlines and branded/specialty drug-price trends as sector-level hedging triggers. If policy risk rises, reduce gross exposure to CAH/MCK rather than rotating between them, since both retain meaningful exposure to the same U.S. pharmaceutical-distribution profit pool.